CSIMarket Company Name, Ticker, Industry, else..
 
Opus Genetics Inc   (NASDAQ: IRD)
 

Opus Genetics Inc's Suppliers Performance

IRD's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
IRD Costs vs Sales of Suppliers Growth

• More on IRD Suppliers






Opus Genetics Inc's Comment on Supply Chain


The APX3330 drug substance has been optimized and is undergoing development for production scale-up in compliance with cGMP requirements. The drug product manufacturer previously supported cGMP manufacturing for 60 mg and 120 mg tablets, and a reformulated 300 mg dose has been developed and tested for bioavailability. Further process development, scale-up, and validation are planned pending a partnership agreement. Under the Viatris License Agreement, Opus Genetics, Inc. granted Viatris an exclusive license to develop, manufacture, and commercialize PS Products in specified territories. Viatris will reimburse development costs and share costs exceeding a defined threshold. Opus Genetics received an initial payment of $35 million and may receive up to $130 million more upon achieving milestones, in addition to tiered royalties on sales.

Opus Genetics Inc's Comment on Supply Chain


The APX3330 drug substance has been optimized and is undergoing development for production scale-up in compliance with cGMP requirements. The drug product manufacturer previously supported cGMP manufacturing for 60 mg and 120 mg tablets, and a reformulated 300 mg dose has been developed and tested for bioavailability. Further process development, scale-up, and validation are planned pending a partnership agreement. Under the Viatris License Agreement, Opus Genetics, Inc. granted Viatris an exclusive license to develop, manufacture, and commercialize PS Products in specified territories. Viatris will reimburse development costs and share costs exceeding a defined threshold. Opus Genetics received an initial payment of $35 million and may receive up to $130 million more upon achieving milestones, in addition to tiered royalties on sales.







IRD's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Opus Genetics Inc 386.67 11.98 -106.93 28
SUBTOTAL 0.00 0.00 0.00 -


Sources: Opus Genetics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Opus Genetics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.